文献速递淋巴瘤

ALCANZA 3期最终数据:维布妥昔单抗对比医生选择方案治疗皮肤T细胞淋巴瘤

Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data.
PubMed 文献 · Blood Adv · 2021-01-01

ALCANZA 3期试验最终分析(中位随访45.9个月)显示,在既往治疗的CD30阳性蕈样肉芽肿或原发性皮肤间变性大细胞淋巴瘤患者中,维布妥昔单抗对比医生选择方案(甲氨蝶呤或贝沙罗汀)显著改善ORR4(54.7% vs 12.5%)和PFS(16.7 vs 3.5个月),周围神经病变多数可完全缓解或改善。

要点

  • 维布妥昔单抗组ORR4达54.7%,显著优于医生选择组的12.5%。
  • 维布妥昔单抗组中位PFS为16.7个月,医生选择组为3.5个月。
  • 周围神经病变(任何级别)44例中86%完全缓解或改善至1-2级。

核心结论

  • 在CD30阳性蕈样肉芽肿或原发性皮肤间变性大细胞淋巴瘤患者中,维布妥昔单抗对比医生选择方案(甲氨蝶呤或贝沙罗汀)可带来显著改善且持久的缓解和更长的PFS。

研究设计与样本

  • 随机3期ALCANZA试验最终分析,中位随访45.9个月。
  • 既往治疗的CD30阳性蕈样肉芽肿或原发性皮肤间变性大细胞淋巴瘤成人患者随机分配至维布妥昔单抗组(n=64)或医生选择组(n=64)。

主要发现

  • 独立评审的ORR4:维布妥昔单抗组54.7% vs 医生选择组12.5%(P < .001)。
  • 完全缓解率:维布妥昔单抗组17.2% vs 医生选择组1.6%(P = .002)。
  • 中位PFS:维布妥昔单抗组16.7个月 vs 医生选择组3.5个月(P < .001)。
  • 至下一次治疗的中位时间:维布妥昔单抗组14.2个月 vs 医生选择组5.6个月(HR 0.27;95%CI 0.17-0.42;P < .001)。
  • 维布妥昔单抗组44例发生任何级别周围神经病变的患者中,86%(38/44)完全缓解(26/44)或改善至1-2级(12/44);18例患者周围神经病变持续(均为1-2级)。

关键数值与推荐

  • 主要终点为持续≥4个月的客观缓解率(ORR4),维布妥昔单抗组54.7% vs 医生选择组12.5%。
  • 完全缓解率:维布妥昔单抗组17.2% vs 医生选择组1.6%。
  • 中位PFS:维布妥昔单抗组16.7个月 vs 医生选择组3.5个月。
  • 至下一次治疗的中位时间:维布妥昔单抗组14.2个月 vs 医生选择组5.6个月(HR 0.27;95%CI 0.17-0.42)。

临床怎么用

  • 对于既往治疗的CD30阳性蕈样肉芽肿或原发性皮肤间变性大细胞淋巴瘤患者,维布妥昔单抗较甲氨蝶呤或贝沙罗汀显著改善持久缓解率和PFS。
  • 治疗期间需监测周围神经病变,多数事件可完全缓解或改善至低级别。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The primary analysis of the phase 3 ALCANZA trial showed significantly improved objective responses lasting ≥4 months (ORR4; primary endpoint) and progression-free survival (PFS) with brentuximab vedotin vs physician's choice (methotrexate or bexarotene) in CD30-expressing mycosis fungoides (MF) or primary cutaneous anaplastic large-cell lymphoma (C-ALCL). Cutaneous T-cell lymphomas often cause pruritus and pain; brentuximab vedotin improved skin symptom burden with no negative effects on quality of life. We report final data from ALCANZA (median follow-up, 45.9 months). Adults with previously treated CD30-expressing MF/C-ALCL were randomly assigned to brentuximab vedotin (n = 64) or physician's choice (n = 64). Final data demonstrated improved responses per independent review facility with brentuximab vedotin vs physician's choice: ORR4; 54.7% vs 12.5% (P < .001); complete response, 17.2% vs 1.6% (P = .002). Median PFS with brentuximab vedotin vs physician's choice was 16.7 months vs 3.5 months (P < .001). Median time to the next treatment was significantly longer with brentuximab vedotin than with physician's choice (14.2 vs 5.6 months; hazard ratio, 0.27; 95% confidence interval, 0.17-0.42; P < .001). Of 44 patients in the brentuximab vedotin arm who experienced any-grade peripheral neuropathy, (grade 3, n = 6; grade 4, n = 0), 86% (38 of 44) had complete resolution (26 of 44) or improvement to grades 1 and 2 (12 of 44). Peripheral neuropathy was ongoing in 18 patients (all grades 1-2). These final analyses confirm improved, clinically meaningful, durable responses and longer PFS with brentuximab vedotin vs physician's choice in CD30-expressing MF or C-ALCL. This trial was registered at https://www.clinicaltrials.gov as #NCT01578499.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Horwitz SM, Scarisbrick JJ, Dummer R, et al. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data. Blood Adv. 2021. PMID: 34507350. doi:10.1182/bloodadvances.2021004710

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。